V591 Uses, Dosage, Side Effects and more
The V591 vaccine, part of Merck’s COVID-19 vaccine programming, was developed using a modified measles vaccine virus as a vector for COVID-19 antigen delivery. Through Merck’s acquisition of Thermis in May 2020, they were able to leverage Thermis’ platform knowledge and accelerate the development of V591 to phase I clinical trials (NCT04498247).
| Trade Name | V591 |
| Generic | V591 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
